NCT02911844View on ClinicalTrials.gov

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

December 5, 2018

Study Completion Date

December 5, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Fulvestrant

Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02911844 - Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter